Lemtrada Advisory Committee’s Flexibility May Not Make FDA Bend
Executive Summary
Panel agrees with agency that Genzyme’s pivotal trials for MS drug don’t meet FDA approval standards, then casts conflicting votes supporting drug.
You may also be interested in...
Lemtrada A Game Changer In MS, Genzyme Researchers Say
The paradigm shift long-lasting Lemtrada will excite, along with Aubagio’s gains since its launch in October, put Sanofi well on the road to its goal of multiple sclerosis leadership, Genzyme research execs say.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.
Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: